X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ELDER PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ELDER PHARMA GSK PHARMA/
ELDER PHARMA
 
P/E (TTM) x 67.7 -0.2 - View Chart
P/BV x 11.9 0.1 11,772.9% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 GSK PHARMA   ELDER PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
ELDER PHARMA
Jun-14
GSK PHARMA/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs3,838380 1,010.0%   
Low Rs2,637188 1,402.7%   
Sales per share (Unadj.) Rs354.2491.2 72.1%  
Earnings per share (Unadj.) Rs39.8-3.2 -1,249.8%  
Cash flow per share (Unadj.) Rs42.914.4 297.5%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.9376.5 62.9%  
Shares outstanding (eoy) m84.7020.54 412.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.10.6 1,580.9%   
Avg P/E ratio x81.4-89.3 -91.2%  
P/CF ratio (eoy) x75.519.7 383.1%  
Price / Book Value ratio x13.70.8 1,811.5%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2165,833 4,700.8%   
No. of employees `0004.7NA-   
Total wages/salary Rs m4,8302,179 221.7%   
Avg. sales/employee Rs Th6,387.0NM-  
Avg. wages/employee Rs Th1,028.3NM-  
Avg. net profit/employee Rs Th717.1NM-  
INCOME DATA
Net Sales Rs m30,00010,089 297.4%  
Other income Rs m728257 283.8%   
Total revenues Rs m30,72810,346 297.0%   
Gross profit Rs m4,190-792 -529.1%  
Depreciation Rs m263361 72.8%   
Interest Rs m02,756 0.0%   
Profit before tax Rs m4,655-3,653 -127.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4573,713 12.3%   
Tax Rs m1,744125 1,393.5%   
Profit after tax Rs m3,368-65 -5,153.8%  
Gross profit margin %14.0-7.8 -177.9%  
Effective tax rate %37.5-3.4 -1,093.5%   
Net profit margin %11.2-0.6 -1,733.2%  
BALANCE SHEET DATA
Current assets Rs m16,7429,240 181.2%   
Current liabilities Rs m7,2029,998 72.0%   
Net working cap to sales %31.8-7.5 -423.4%  
Current ratio x2.30.9 251.5%  
Inventory Days Days5246 111.9%  
Debtors Days Days2160 34.7%  
Net fixed assets Rs m8,63510,124 85.3%   
Share capital Rs m847206 411.8%   
"Free" reserves Rs m19,2225,582 344.3%   
Net worth Rs m20,0697,734 259.5%   
Long term debt Rs m104,889 0.2%   
Total assets Rs m30,03822,882 131.3%  
Interest coverage xNM-0.3-  
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x1.00.4 226.5%   
Return on assets %11.211.8 95.3%  
Return on equity %16.8-0.8 -1,986.0%  
Return on capital %25.522.3 114.1%  
Exports to sales %03.0 0.0%   
Imports to sales %00.4 0.0%   
Exports (fob) Rs mNA307 0.0%   
Imports (cif) Rs mNA43 0.0%   
Fx inflow Rs m528307 172.2%   
Fx outflow Rs m7,193125 5,740.6%   
Net fx Rs m-6,665181 -3,676.2%   
CASH FLOW
From Operations Rs m2,36011,754 20.1%  
From Investments Rs m3,008-561 -536.7%  
From Financial Activity Rs m-5,108-6,762 75.5%  
Net Cashflow Rs m2604,432 5.9%  

Share Holding

Indian Promoters % 0.0 39.6 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 7.5 136.0%  
FIIs % 23.8 16.8 141.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 36.1 42.7%  
Shareholders   102,036 16,479 619.2%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   AJANTA PHARMA  FDC LTD.  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare GSK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Rising Oil Prices; RBI Minutes and Top Stocks in Action Today(Pre-Open)

Indian share markets surged on Wednesday, snapping a two-day losing streak led by gains Reliance Industries and bank stocks.

Related Views on News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 20, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS